ISB 2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells. Developed using IGI's proprietary BEAT® protein platform, ...

Glenmark's cancer drug delivers high response in phase-1 trial, shows 74% response: Our Bureau, Mumbai Tuesday, June 3, 2025, 16:45 Hrs [IST] Ichnos Glenmark Innovation (IGI), a g ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

The company will halt further development of imvotamab or CD20 x CD3 and IGM-2644 or CD38 x CD3, both IgM-based bispecific antibody T cell engagers, for autoimmune diseases. Imvotamab or CD20 x ...

Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed and refractory (R/R ...

CD3 (including its subunits CD3ε, CD3δ, CD3γ, and CD3ζ) is the central component of the TCR-CD3 complex and is crucial for recognizing T cells and responding to antigens. Every subunit of CD3 ...

an investigational first-in-class BCMA × CD38 × CD3-targeting trispecific antibody for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). These data, presented as a ...

The early-stage trial results signal promise for ISB 2001, a first-in-class trispecific antibody being developed for patients ...